Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Status:
Suspended
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and
survival period. by performing a phase II study of this combination in patients with
inoperable or with postoperative gastric cancer